Via Newswise, 12 November 2024: University of Wisconsin–Madison researchers targeting a group of hereditary neurodegenerative diseases have found success using a gene therapy treatment in an animal model. The approach, which uses CRISPR-Cas9 genome editing technology, offers a strategy that could one day treat motor neuron diseases in humans. Hereditary spastic paraplegia, or HSP, is…
Category: Movement Disorders
Understanding Tourette syndrome
Tourettes Action have created a new e-learning module, Understanding Tourette syndrome for GPs. This course has been created with the help of Dr Kate Szymankiewicz, a GP with an interest in Tourette syndrome and clinical experts from the Tourettes Action Board of Trustees. In this module, you will learn what Tourette syndrome is, co-occurring features…
Parkinson’s disease therapy Vyalev gets FDA approval
AbbVie announced on 17th October that the US Food and Drug Administration (FDA) has approved VYALEV™ (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD). The treatment is approved in 35 countries. The approval was supported by…
Ophthalmic acid – its role in motor function control
Brain molecule reverses movement deficits of Parkinson’s, offering new therapeutic target October 4th 2024: A research team from the University of California, Irvine is the first to reveal that a molecule in the brain – ophthalmic acid – unexpectedly acts like a neurotransmitter similar to dopamine in regulating motor function, offering a new therapeutic target…
Cannabis-based medicine for neurodegenerative diseases
Avextra announces the approval of NEUROBIS by the Italian Medicines Agency: A Phase II clinical trial Avextra AG, a European manufacturer and developer of Cannabis-based medicines located in Germany, has announced that both the Italian Medicines Agency AIFA and the Italian Ministry of Health have granted formal approval for a multi-centre Phase II study to…
Spinocerebellar ataxia – troriluzole topline results
Biohaven achieves positive results in pivotal study September 23 2024 Biohaven Ltd have announced positive topline results from pivotal Study BHV4157-206-RWE (NCT06529146) demonstrating the efficacy of troriluzole on the mean change from baseline in the f-SARA after 3 years of treatment. The study achieved the primary endpoint and showed statistically significant improvements on the f-SARA…
Deutetrabenazine for Tardive Dyskinesia
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients 21st September 2024: Teva Pharmaceutical Industries Ltd has announced that a new analysis from the European cohort of the RIM-TD open-label extension (OLE) study revealed that deutetrabenazine treatment of patients with Tardive Dyskinesia (TD) was associated with long term improvement of TD symptoms….
